Systemic Lupus Erythematosus

Corbus has amended the protocol to one of its existing Investigational New Drug (IND) applications with the U.S. Food and Drug Administration to initiate a Phase 2 clinical study of anabasum for the treatment of systemic lupus erythematosus. The Phase 2 study will be funded by a grant from the National Institutes of Health (NIH) to the Feinstein Institute for Medical Research and is expected to commence in the third quarter of 2017.

  • Primary Endpoints: Efficacy in inflammatory pain in subjects with active musculoskeletal disease
  • Secondary Endpoints: Efficacy in overall disease activity, musculoskeletal disease, and quality of life, safety and tolerability, biomarkers of inflammation, metabolipidomic profile, and pharmacokinetics
  • Patient Number: 100 adults with SLE at 10 U.S. sites
  • Treatment Duration: 84 days treatment with 28 days follow-up

Study News